Benefit Checks for Biologics Before the Patient Arrives

Benefit checks for biologics are the difference between a visit that gets paid and a visit that becomes a write-off. A routine eligibility ping tells you the patient has coverage. It does not tell you whether this therapy, from this provider, in this place of service, under this plan, is covered today, which is the only question that matters before the appointment goes on the calendar.

In most specialties the verification question is binary. Is the plan active, and what is the copay. The front desk checks it the day before, and if something is wrong the practice loses a visit fee.

High-cost therapy inverts the stakes. The visit itself is a small part of the exposure, and the failure is discovered weeks later when the claim comes back. By then the product has been given, the practice has paid for it, and the recovery options are appeals and patient balances that nobody wanted.

What makes it operationally hard is that the answer lives in several places at once. Coverage rules for the therapy, whether authorization is required and for how long, which benefit it falls under, and whether the ordering provider is enrolled with that plan. None of those are answered by a single eligibility response.

The practices that stay whole on this work move all of it in front of the appointment, and they make the appointment date depend on the answer.

Authorization is the gate, and denials are not rare

Prior authorization is the mechanism payers use to control high-cost therapy, and it is applied at scale. KFF analysis found that in 2024, Medicare Advantage insurers denied 4.1 million prior authorization requests in full or in part, which is 7.7% of all requests, slightly higher than the 6.4% denied in 2023.

The more useful number for a practice administrator is what happens next. Most appeals succeed. In the same analysis, 80.7% of appealed denials were partially or fully overturned in 2024, and across all the years examined more than eight in ten appeals overturned the initial denial.

That combination describes the actual operational risk. The first answer is frequently wrong in the practice’s favor, and getting it corrected costs staff time that has to be spent before the therapy is given rather than after. A denial discovered at the appeal stage after treatment is a financial event. The same denial discovered before scheduling is a paperwork task.

So the target is not a lower denial rate. It is making sure no high-cost visit reaches the calendar without its authorization status known, and making sure the appeals work starts the day the denial arrives rather than the week the claim bounces.

The appointment date should depend on the authorization

The scheduling rule that protects this revenue is one most practices apply informally and inconsistently.

A visit that needs no authorization can be booked same day or next day. A visit that does need one has its earliest offer set out far enough that the authorization team can actually submit and hear back. In practice this generalizes to plan type as much as to service, with some plan categories reliably slower than others.

When that rule lives in a scheduler’s head, it survives until the scheduler is on holiday. At a multi-site pain practice, six to eight percent of procedures were being scheduled outside the authorization window by human schedulers, which is a small percentage that represents a large amount of money at specialty drug prices.

Encoding it is straightforward once someone decides to. The appointment type carries whether authorization is required, the plan carries how much lead time it typically needs, and the earliest offerable date is computed from both. The patient hears one date, which is the date the visit can actually be paid for.

The reschedule case is the one that quietly breaks. Moving an appointment does not carry the authorization with it, so the new visit is not attached to the existing approval. The rule that follows is unintuitive and important. An appointment whose authorization has not come back can be pushed later, never pulled earlier, and anything that offers slots has to know that before it offers a nice open Tuesday.

Verify the provider, not only the patient

The second failure mode has nothing to do with the therapy and everything to do with who is delivering it.

Whether a provider is enrolled with a given payer resolves per provider, per payer, per state, and sometimes per treatment type. All of those have to be true before the visit can be offered, and the grid that holds them almost never lives inside the practice management system. It is a spreadsheet maintained by whoever handles credentialing.

Booking a patient with a provider who is not enrolled in their plan produces a visit that happens and a claim that dies weeks later. In a specialty where the product cost dwarfs the professional fee, that is not a small write-off.

Most practices cannot hand over a clean enrollment matrix because it is genuinely messy. The workable artifact is the inverse and it is much smaller, which is a per-provider list of the plans that provider does not take. That fits on a page, it is maintainable by the credentialing coordinator, and it is enough to stop the automation from offering the wrong provider.

New providers need one more field, which is a start date for each payer. Enrollment completes on a date, and a rule that turns itself on at the right time is better than a note reminding someone to check in six weeks.

What the athenaOne side of this looks like

The reason to run this inside athenaOne rather than in a spreadsheet is that the result has to be visible to everyone who touches the appointment.

The eligibility response and the plan’s benefit detail both belong on the patient’s insurance record. Coverage specifics for the therapy, once obtained, belong there too rather than in an email thread. The authorization and its expiry attach to the visit that depends on them. The appointment carries the insurance it was verified against, so a coverage change between booking and arrival is a visible mismatch rather than a surprise.

What automation adds is the part staff cannot sustain, which is doing this repeatedly and on time. Re-verification before the visit rather than only at booking, because plans change mid-year and a check run in November is not evidence about January. Chasing an authorization that has been sitting with a payer past its usual turnaround. Watching for the coverage change that turns a booked series into an unfunded one.

The federal direction of travel supports this. CMS finalized the Interoperability and Prior Authorization rule, which requires affected payers to build prior authorization APIs and to send decisions and denial reasons within set timeframes. Practices that already treat authorization status as structured data attached to the appointment will be able to use that. Practices running it on fax and phone will not.

None of this touches what gets ordered. Which therapy a patient receives is the physician’s call. The front office is establishing whether the plan will pay for what was ordered, and getting that answer before the patient is sitting in the chair.

The numbers that show it is working

Verification programs are easy to declare finished and hard to prove, so pick measures that would move if the work stopped.

Start with the share of high-cost visits that arrived with a verified benefit and a current authorization on file. That is the whole objective stated as a percentage, and it should be close to complete rather than merely improving.

Then watch the gap between booking date and authorization decision date. If visits are being booked before submissions go out, the scheduling rule is not actually encoded, whatever the policy says.

Track re-verification separately from initial verification. Coverage checked once at booking and never rechecked is the most common way a clean process still produces a denied claim.

Finally count the appeals. Not how many were filed, but how long they took to start after the denial arrived. Given how often appeals succeed, days lost at the front of that process are the most expensive days in the workflow.

Key Takeaways

Treat the eligibility response as the start of verification, since it does not answer whether this therapy under this plan is covered today.
Make the earliest offerable appointment date depend on whether authorization is required and how long that plan usually takes.
Remember that rescheduling breaks the authorization link, so a visit awaiting approval can be pushed later but never pulled earlier.
Ask credentialing for the per-provider list of plans that provider does not take, which is smaller and more maintainable than the full enrollment grid.
Give each provider a per-payer enrollment start date so the rule turns itself on instead of waiting for someone to check.
Re-verify coverage before the visit rather than only at booking, because plans change mid-year and a series outlives its check.
Measure days between denial and the start of the appeal, since most appealed denials are overturned and the delay is the expensive part.

The money in this specialty is decided before anyone walks in. A benefit check that answers the specific question, an appointment date that respects the authorization window, and a provider who is actually enrolled with the plan are three pieces of front-office work that together decide whether a high-cost visit is revenue or a write-off.

Sources